Abstract
PD-L1 expression in pleural effusions (PE) of lung adenocarcinoma (ADC) was compared with pleural biopsies and the positive expression in PE was correlated with survival time. The matched slices from same patient's pleura and PE were collected which both were pathologically verified positive. Immunohistochemistry (IHC) was used to detect PD-L1 expression. A total of 51 eligible cases were enrolled, including 30 males and 21 females. The average age was (67.06 ± 12.10) years. PD-L1 expression wasn't statistically significant in pleura and cell masses (P > 0.05) and the correlation was statistically significant (r = 0.585, P = 0.000). Using an IHC scores of 5 point as a cutoff, positive PD-L1 expression in the pleura was 11.63% and that in the cell masses was 23.26%, and difference was significant (P < 0.05). Among 35 cases underwent systemic anti-tumor treatment, the mean survival time with positive PD-L1 expression in PE was 17.370 ± 1.827 months, which was significantly shorter than that with the negative (29.944 ± 2.671 months). Positive PD-L1 expression in PE is higher than in the pleura and their correlation is well. It may predict the short survival time after systemic anti-tumor treatment.
Introduction
Non-small-cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality worldwide, frequently diagnosed at advanced stages. While immunotherapies targeting the PD-1/PD-L1 pathway have transformed the treatment landscape, identifying responsive patients through PD-L1 biomarker testing is essential. Traditionally, tissue biopsies are the "gold standard" for this testing; however, they are invasive and often difficult to obtain in advanced cases. This study investigates whether pleural effusion (PE)—a common fluid buildup in advanced lung cancer—can serve as a reliable and potentially more sensitive surrogate for PD-L1 testing.
Methodology and Patient Cohort
The researchers conducted a controlled study of 51 patients with Stage IV pulmonary adenocarcinoma. For each patient, matched samples were collected: a physical pleural biopsy (PT) and a cell block created from centrifuged pleural effusion fluid (PE).
PD-L1 expression was detected using Immunohistochemistry (IHC) and evaluated with a semi-quantitative scoring system (0–5 points) that combined staining intensity and the percentage of positive tumor cells. Different cutoff values were analyzed to determine the optimal threshold for clinical significance.
Key Results
Consistency and Sensitivity
The study found a statistically significant correlation between PD-L1 expression in the fluid and the tissue (r = 0.585 to 0.605, P = 0.000). Notably, at a strict IHC score cutoff of ≥ 5, the fluid samples demonstrated a higher rate of PD-L1 positivity (23.26%) compared to tissue biopsies (11.63%). This suggests that pleural effusion may capture tumor heterogeneity more effectively than single-point biopsies by collecting cells shed from various metastatic sites.
Prognostic Value
PD-L1 status in pleural effusion emerged as a significant predictor of survival. For the 35 patients receiving systemic anti-tumor treatments (chemotherapy or EGFR-TKIs):
- PD-L1 Negative in PE: Mean survival of 29.9 months.
- PD-L1 Positive in PE: Mean survival of 17.4 months.
This survival gap was statistically significant (P = 0.034), highlighting PD-L1 in PE as a marker for increased tumor aggressiveness and poor prognosis.
Discussion and Limitations
The findings validate the use of pleural effusion as a viable "liquid biopsy" for PD-L1 assessment. The higher sensitivity in PE suggests it may be superior to traditional biopsy for identifying high-risk patients. However, the study is limited by its relatively small sample size (n=51) and the fact that the cohort was treated with conventional therapies rather than modern immune checkpoint inhibitors. Future research should focus on multi-center trials to determine if PE PD-L1 levels can specifically predict the efficacy of immunotherapy drugs like pembrolizumab.
Summary updated